Cellosaurus logo
expasy logo

Cellosaurus WM9 R (CVCL_E3AH)

[Text][XML][JSON]
Cell line name WM9 R
Accession CVCL_E3AH
Resource Identification Initiative To cite this cell line use: WM9 R (RRID:CVCL_E3AH)
Comments Selected for resistance to: ChEBI; CHEBI_90851; Cobimetinib (Cotellic).
Selected for resistance to: ChEBI; CHEBI_63637; Vemurafenib (Zelboraf; PLX4032).
Derived from site: Metastatic; Left axillary lymph node; UBERON=UBERON_0001097.
Sequence variations
  • Gene deletion; HGNC; HGNC:9588; PTEN; Zygosity=Hemizygous (from parent cell line).
  • Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
Disease Melanoma (NCIt: C3224)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_6806 (WM9)
Sex of cell Male
Age at sampling Age unspecified
Category Cancer cell line
Publications

PubMed=39175042; DOI=10.1186/s12964-024-01788-3; PMCID=PMC11342534
Magdalena Kot, Aleksandra Simiczyjew, Justyna Wadzynska, Marcin Zietek, Rafa Adam Matkowski, Dorota Nowak;
Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib).
Cell Commun. Signal. 22:410.1-410.21(2024)

Entry history
Entry creation10-Sep-2024
Last entry update19-Dec-2024
Version number2